ArticleCureus2026
Multidisciplinary Management of Paraneoplastic Anti-N-Methyl-D-Aspartate Receptor Encephalitis Associated With Ovarian Teratoma: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-N-methyl-D-aspartate (NMDA) receptor encephalitis is a severe autoimmune encephalitis often associated with ovarian teratomas and characterized by a rapidly progressive neuropsychiatric syndrome, seizures, dyskinesias, a decreased level of consciousness, and autonomic instability. Antibodies targeting the GluN1 subunit lead to internalization of synaptic NMDA receptors, a mechanism associated with potential neurological recovery when treatment is initiated in a timely manner. Early recognition and initiation of immunotherapy, together with tumor resection, play a key role in improving patient outcomes. We present the case of a 20-year-old Hispanic woman with subacute neuropsychiatric deterioration and focal seizures beginning in late November 2025, in whom diagnostic evaluation revealed anti-NMDA receptor antibodies and a large ovarian mature cystic teratoma. Due to high clinical suspicion, early surgical resection (<72 hours) and first-line immunotherapy were initiated before antibody confirmation. Following stepwise escalation to plasma exchange, IV immunoglobulin, and second-line therapy with rituximab, the patient demonstrated gradual and sustained neurological recovery after five weeks of inpatient treatment. This case highlights the importance of a multidisciplinary approach in the management of paraneoplastic anti-NMDA receptor encephalitis and supports the safety of ultra-early surgical resection in tumor-associated cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.